The product is stated to be in post-phase three development-stage and combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable needs to be replaced every two days and can be worn using an adhesive patch or near the infusion site.
Phillips-Medisize built devices and supplied key data to support the FDA new drug application (NDA) and will provide the final assembly, testing and quality control on the product. More so, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device.
Matt Jennings, CEO and president of Phillips-Medisize, said: “This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programmes with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both.”
The product is slated to be launched in the second half of the 2020’s fiscal year. The product could also be brought onto Phillips-Medisize’s connected health platform in the future, making it possible to capture and communicate data between patient and provider in order to help monitor adherence.
